Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Purdue Pharma has introduced Butrans (buprenorphine) Transdermal System CIII by prescription for the management of moderate to severe chronic pain in patients who needs continuous, around-the-clock opioid analgesic for an extended period of time.
Subscribe to our email newsletter
Butrans Transdermal System delivers continuous release of buprenorphine for seven days, Purdue Pharma said.
Purdue Pharma has jointly developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans with the US Food and Drug Administration.
Georgetown University adjunct faculty member Joseph Pergolizzi said Butrans may provide healthcare professionals with a new tool for appropriate adult patients with moderate to severe chronic pain who meet the indication of the product.